Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects

International Journal of Neuropsychopharmacology

Volumn 8, Issue 2, 2005, Pages 203-213

  Johnson, Bankole A ^a,b   Roache, John D ^a   Ait Daoud, Nassima ^a   Wallace, Christopher ^a   Wells, Lynda ^a   Dawes, Michael ^a   Wang, Yanmei ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Calcium channel antagonist; Craving; Humans; Isradipine; Methamphetamine; Reinforcement; Subjective effects

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; ISRADIPINE; METHAMPHETAMINE; PARACETAMOL; PLACEBO;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CONDITIONING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECISION MAKING; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG EFFECT; DRUG RELEASE; EUPHORIA; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; IMMEDIATE DRUG RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; REWARD; SELF REPORT; SUBSTANCE ABUSE; SUSTAINED DRUG RELEASE; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISRADIPINE; MALE; MIDDLE AGED; QUESTIONNAIRES; REINFORCEMENT (PSYCHOLOGY); TIME FACTORS;

EID: 20044396621     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704005036     Document Type: Article

References (39)

1. Batki SL, Moon J, Delucchi K, Hersch D, Bradley M, Aguillon-Doms C, Mendelson J, Jones RT, Panganiban T, Everhart T, Mengis M, Smolar S, Helmke H, Jacob III P (2001). Amlodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis [Abstract]. Drug and Alcohol Dependence 63 (Suppl. 1), S12.
2. Calcagnetti DJ, Schechter MD (1992). Psychostimulant-induced activity is attenuated by two putative dopamine release inhibitors. Pharmacology, Biochemistry, and Behavior 43, 1023-1031.
3. Cho AK, Melega WP (2002). Patterns of methamphetamine abuse and their consequences. Journal of Addictive Diseases 21, 21-34.
4. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Research. Brain Research Reviews 36, 1-22.
5. Dawirs RR, Teuchert-Noodt G, Nossoll M (1997). Pharmacologically induced neural plasticity in the prefrontal cortex of adult gerbils (Meriones unguiculatus). European Journal of Pharmacology 327, 117-123.
6. Di Paolo T (1994). Modulation of brain dopamine transmission by sex steroids. Reviews in the Neurosciences 5, 27-41.
7. Eisch AJ, O'Dell SJ, Marshall JF (1996). Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine. Synapse 22, 217-225.
8. Ernst T, Chang L, Leonido-Yee M, Speck O (2000). Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54, 1344-1349.
9. Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D (1994). Imipramine for the treatment of cocaine and methamphetamine dependence. Journal of Addictive Diseases 13, 201-216.
10. Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D (1996). A controlled trial of imipramine for the treatment of methamphetamine dependence. Journal of Substance Abuse Treatment 13, 493-497.
11. Ghosh A, Ginty DD, Bading H, Greenberg ME (1994). Calcium regulation of gene expression in neuronal cells. Journal of Neurobiology 25, 294-303.
12. Grace AA, Bunney BS (1984). The control of firing pattern in nigral dopamine neurons: burst firing. Journal of Neuroscience 4, 2877-2890.
13. Griffiths RR, Rush CR, Puhala KA (1996). Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Experimental and Clinical Psychopharmacology 4, 97-106.
14. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993). Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behavioural Pharmacology 4, 3-13.
15. Haertzen CA, Hill HE, Belleville RE (1963). Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 4, 155-166.
16. Halkitis PN, Parsons JT, Stirratt MJ (2001). A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. Journal of Homosexuality 41, 17-35.
17. Hemby SE, Johnson BA, Dworkin SI (1997). Neurobiological basis of drug reinforcement. In: Johnson BA, Roache JD (Eds.), Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior (pp. 137-169). Philadelphia: Lippincott-Raven.
18. Johnson BA, Roache JD, Bordnick PS, Ait-Daoud N (1999). Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. Psychopharmacology 144, 295-300.
19. King TS, Steger RW, Morgan WW (1986). Effect of ovarian steroids to stimulate region-specific hypothalamic 5-hydroxytryptamine synthesis in ovariectomized rats. Neuroendocrinology 42, 344-350.
20. Koob GF (1992). Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends in Pharmacological Sciences 13, 177-184.
21. Lamb RJ, Henningfield JE (1994). Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. Journal of the Experimental Analysis of Behavior 61, 169-180.
22. Marshall JF, O'Dell SJ, Weihmuller FB (1993). Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. Journal of Neural Transmission. General Section 91, 241-254.
23. McCann UD, Ricaurte GA (2004). Amphetamine neurotoxicity: accomplishments and remaining challenges. Neuroscience and Biobehavioral Reviews 27, 821-826.
24. 11C]WIN-35,428. Journal of Neuroscience 18, 8417-8422.
25. McNair DM, Lorr M, Droppleman LF (1971). Manual of the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service.
26. Mills K, Arsah TA, Ali SF, Shockley DC (1998). Calcium channel antagonist isradipine attenuates cocaine-induced motor activity in rats: correlation with brain monoamine levels. Annals of the New York Academy of Sciences 844, 201-207.
27. Overton PG, Clark D (1997). Burst firing in midbrain dopaminergic neurons. Brain Research. Brain Research Reviews 25, 312-334.
28. Pucilowski O, Plaznik A, Overstreet DH (1995). Isradipine suppresses amphetamine-induced conditioned place preference and locomotor stimulation in the rat. Neuropsychopharmacology 12, 239-244.
29. Rawson RA, Anglin MD, Ling W (2002). Will the methamphetamine problem go away? Journal of Addictive Diseases 21, 5-19.
30. Roache JD, Meisch RA (1995). Findings from self-administration research on the addiction potential of benzodiazepines. Psychiatric Annals 25, 153-157.
31. Roache JD, Meisch RA, Henningfield JE, Jaffe JH, Klein S, Sampson A (1995). Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures. Pharmacology, Biochemistry, and Behavior 50, 171-179.
32. Roche E, Prentki M (1994). Calcium regulation of immediate-early response genes. Cell Calcium 16, 331-338.
33. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
34. SAS Institute Inc. (1999). SAS User's Guide: Statistics, Version 8.2 (8th edn). Gary, NC: SAS Institute Inc.
35. Sher E, Biancardi E, Passafaro M, Clementi F (1991). Physiopathology of neuronal voltage-operated calcium channels. FASEB Journal 5, 2677-2683.
36. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P (2001). Treatment for amphetamine dependence and abuse. Cochrane Database of Systematic Reviews 4, CD003022.
37. U.S. Department of Health and Human Services (1997). Annual Data, SAMHSA/CSAT. Methamphetamine the Drug and Its Use. U.S. Department of Health and Human Services Publication No. SMA 96-8013.
38. Volkow ND, Chang L, Wang G-J, Fowler JS, Franceschi D, Gatley SJ, Wong CT, Hitzemann RJ, Pappas NR (1999). In vivo evidence that methamphetamine abuse produces long lasting changes in dopamine transporters in the human brain [Abstract]. Journal of Nuclear Medicine 40, 110.
39. Wise RA, Bauco P, Carlezon Jr. WA, Trojniar W (1992). Self-stimulation and drug reward mechanisms. Annals of the New York Academy of Sciences 654, 192-198.